联合靶向p53依赖与非依赖通路清除骨髓纤维化造血干/祖细胞
本研究将imipridone类药物ONC201与MDM2拮抗剂RG7112联用,旨在通过激活p53及TRAIL/死亡受体通路清除骨髓纤维化(MF)造血干/祖细胞(HSPC)。与单药相比,联合用药对MF CD34+细胞诱导更高程度的凋亡,并减少JAK2V617F+及钙网蛋白突变集落,同时允许JAK2野生型集落持续存在或出现。
要点
- ONC201联合RG7112可协同促进MF CD34+细胞凋亡。
- 联合用药减少JAK2V617F+和钙网蛋白突变集落形成。
- 联合用药保留或允许JAK2野生型集落持续存在。
核心结论
- ONC201联合RG7112可能成为治疗骨髓纤维化患者的潜在有效策略。
研究设计与样本
- 本研究为体外研究,使用骨髓纤维化患者CD34+细胞,比较ONC201与RG7112单药及联合用药的效果。
主要发现
- 与单药相比,ONC201联合RG7112通过激活p53依赖和非依赖通路,促进更高程度的MF CD34+细胞凋亡。
- ONC201联合RG7112减少从MF CD34+细胞中检测的JAK2V617F+和钙网蛋白突变集落数量。
- ONC201联合RG7112允许JAK2野生型集落持续存在或出现。
临床怎么用
- 联合靶向p53依赖与非依赖通路可能作为清除MF造血干/祖细胞的策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current therapy for myelofibrosis (MF) results in a limited prolongation of patient survival. In order to improve treatment outcomes, we developed a strategy to effectively deplete MF hematopoietic stem/progenitor cells (HSPCs). In the present study, an imipridone, ONC201, was combined with RG7112, an antagonist of MDM2, a p53 negative regulator, to activate downstream events of the p53 and TNF-related apoptosis-inducing ligand (TRAIL)/death receptor (DR) pathways. As compared to treatment with the individual drugs, the combination of ONC201 and RG7112 promoted greater degrees of apoptosis of MF CD34+ cells through activation of both p53-dependent and -independent pathways. Importantly, treatment with ONC201-RG7112 not only decreased the number of JAK2V617F+ and calreticulin mutated colonies assayed from MF CD34+ cells, but allowed for the persistence or appearance of JAK2 wild type colonies. Treatment with ONC201 combined with RG7112 could be a potentially effective strategy for treating MF patients.
引用
- Lu M, Xia L, Elmansy N, et al. Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells. Leukemia. 2021. PMID: 34642468. doi:10.1038/s41375-021-01446-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。